Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
On 07/02/2025, Sight Sciences (SGHT) Chief Commercial Officer Matthew Link filed a Form 4 reporting the sale of 4,889 common shares at an average price of $4.098 per share.
The filing notes the shares were sold solely to satisfy the executive’s tax liability related to the vesting of restricted stock units. Following the transaction, Link continues to hold 832,293 shares of SGHT, retaining more than 99% of his previous direct ownership. No derivative securities were acquired or disposed of.
The sale represents a routine, low-volume insider disposition—approximately 0.6% of the executive’s holdings—and is unlikely to materially affect investor sentiment or the company’s share-price outlook.